1. Scrip
  2. >>New Products

Analysts Admire Argenx's Vyvgart Launch

Pipeline-In-A-Product Off To Strong Start

 
• By Kevin Grogan

The generalized myasthenia gravis-approved drug passed the $20m mark in sales for the first quarter, comfortably surpassing analyst estimates.

Rocket_Launch
• Source: Shutterstock

argenx N.V.'s rare disease drug Vyvgart has flown out of the blocks following the therapy's recent approval in the US for generalized myasthenia gravis (gMG), with sales in the first quarter smashing analyst forecasts.

The US Food and Drug Administration gave the green light to Vyvgart (efgartigimod), Argenx’s first approved product, on 17 December for adults who are anti-acetylcholine receptor (AChR) antibody positive, a sub-group that represents 85% of the total gMG population. The thumbs-up made it the first therapy to be approved from the FcRn inhibitor class and the reception from physicians has been a warm one

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.